Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 28;12(12):1970.
doi: 10.3390/jpm12121970.

Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study

Kye-Yeung Park  1 , Sangmo Hong  2 , Kyung-Soo Kim  3 , Kyungdo Han  4 , Cheol-Young Park  5
Affiliations

Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study

Kye-Yeung Park et al. J Pers Med. .

Abstract

Despite its hepatoprotective effects and favorable metabolic effects, the association between carnitine-orotate complex (Godex®) intake and mortality has never been investigated. We enrolled 13,413 adults who underwent national health examination and were prescribed the carnitine-orotate complex. Subjects were classified into three groups based on duration of using carnitine-orotate complex: <30, 30−180, and ≥180 days and were followed-up until 2019. Hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality were estimated using Cox proportional hazards regression. During the follow-up period, 708 deaths were documented. Adjusted HR of mortality was 0.69 (95% CI 0.51−0.92) in those who used carnitine-orotate complex for ≥180 days compared to those who used it for <30 days. Use of carnitine-orotate complex for ≥180 days was associated with significantly reduced mortality in individuals with metabolic risk factors such as obesity, metabolic syndrome, dyslipidemia, and fatty liver than the shorter period of use. A significant interaction was observed in individuals with type 2 diabetes (HR 0.43, 95% CI 0.29−0.63, p-value 0.001). In this nationwide study, longer use of carnitine-orotate complex was associated with improved mortality compared to a shorter period of use, and the risk reductions were prominent in individuals with metabolic risk factors.

Keywords: cardiometabolic risk factors; carnitine; epidemiologic study; metabolic diseases; mortality.

PubMed Disclaimer

Conflict of interest statement

The funder (Celltrion Pharm) had no role in the design of the study, the collection, analyses, or interpretation of data, the writing of the manuscript, or the decision to publish the results.

Figures

Figure 1
Figure 1
Flow chart of the study population.
Figure 2
Figure 2
Subgroup analysis of all-cause mortality according to duration of carnitine-orotate complex use. HRs (95% CIs) were calculated using a multivariable Cox proportional hazard regression analysis after adjusting for age, sex, income, smoking status, alcohol consumption, physical activity, obesity, hypertension, dyslipidemia, Charlson comorbidity index, serum aspartate transaminase level, serum alanine transferase level, and use of carnitine-orotate complex within 1-year prior to enrollment.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Jun D.W., Kim B.I., Cho Y.K., Kim H.J., Kwon Y.O., Park S.Y., Han S.Y., Baek Y.H., Jung Y.J., Kim H.Y., et al. Efficacy and Safety of Entecavir plus Carnitine Complex (GODEX®) Compared to Entecavir Monotherapy in Patient with ALT Elevated Chronic Hepatitis B: Randomized, Multicenter Open-Label Trials. The GOAL Study. Clin. Mol. Hepatol. 2013;19:165–172. doi: 10.3350/cmh.2013.19.2.165. - DOI - PMC - PubMed
    1. Sin J.S., Jung E.Y., Lee M.H., Kang J.K. Therapeutic Effect of the Godex on the Liver Cirrhosis Induced by CCl4 and Ethanol in the Rat. J. Appl. Pharmacol. 2002;10:200–207.
    1. Park M.-S., Kang J.-S., Chon C.-Y., Paik S.-W., Rim K.-S., Kwak M.-J., Jeon Y.-C., Lee M.-H. Oral Godex Capsule for Chronic Liver Disease:A Double-Blind, Randomized, Multicenter Controlled Trial. J. Korean Soc. Clin. Pharmacol. Ther. 2001;9:151–162. doi: 10.12793/jkscpt.2001.9.2.151. - DOI
    1. Hong E.S., Kim E.K., Kang S.M., Khang A.R., Choi S.H., Park K.S., Jang H.C., Lim S. Effect of Carnitine-Orotate Complex on Glucose Metabolism and Fatty Liver: A Double-Blind, Placebo-Controlled Study. J. Gastroenterol. Hepatol. 2014;29:1449–1457. doi: 10.1111/jgh.12536. - DOI - PubMed
    1. Bae J.C., Lee W.Y., Yoon K.H., Park J.Y., Son H.S., Han K.A., Lee K.W., Woo J.T., Ju Y.C., Lee W.J., et al. Improvement of Nonalcoholic Fatty Liver Disease with Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. Diabetes Care. 2015;38:1245–1252. doi: 10.2337/dc14-2852. - DOI - PubMed

LinkOut - more resources